A study to assess and compare major adverse events related to methotrexate, disease-modifying anti-rheumatic drugs and Janus kinase inhibitors reported to Japanese adverse drug event report database
Latest Information Update: 28 Jun 2022
At a glance
- Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Baricitinib (Primary) ; Baricitinib (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Methotrexate (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
Most Recent Events
- 28 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism